Drugs / VVZ-149
VVZ-149
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04415645 | Feb → Mar 2020 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02644421 | Nov 2015 → Jul 2017 | radiculopathy, sciatica | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02333318 | Jul → Sep 2014 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01905410 | Jul 2013 → Mar 2014 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03997812 | May → Aug 2019 | neuropathy, painful | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03347266 | Dec 2017 → Jul 2018 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02992041 | Dec 2016 → Apr 2018 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02844725 | Jun 2016 → Feb 2017 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02489526 | Sep 2015 → Aug 2016 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02522598 | Aug 2015 → Feb 2016 | — | Vivozon, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05764525 | Jul 2021 → Nov 2022 | neuropathy, painful | Vivozon Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04430088 | Jun → Dec 2020 | neuropathy, painful | Vivozon, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03997838 | May → Aug 2019 | neuropathy, painful | Vivozon, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVZ-149 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02333318 ↗ |
| Known as | VVZ-149 Injection | “Drug: VVZ-149 Injection” NCT01905410 ↗ |
| Known as | VVZ-149 Injections | “The purpose of this phase 3 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections for treating post-operative pain following abdominoplasty.” NCT03997838 ↗1“Drug: VVZ-149 Injections” NCT04430088 ↗ |
| Action | Inhibit | “VVZ-149 is a novel analgesic drug candidate that shows a potential analgesic activity inhibiting GlyT2 and 5HT2A simultaneously.” NCT01905410 ↗ |
| Modality | Small molecule | “VVZ-149 is a small molecule” PMID 34794108 ↗ Nov 2021 |
| Route | Intravenous | “will be given by intravenous infusion for 4 hours.” NCT01905410 ↗ |